Therefore, the biomimetic nanoplatform designed in the present study utilizes anti-HER2 antibodies on the macrophage membrane to specifically recognize HER2 antigen on the tumor cells surface, achieving accurate GEM delivery and precise targeted therapy. Here, ERBB2 is linked to neoplasm.